Trials / Completed
CompletedNCT00721669
A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- ImmunoGen, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Primary objective is to evaluate the safety and PK of IMGN388
Detailed description
The secondary objectives are to assess the pharmacodynamics, immunogenicity, and tumor response of IMGN388 administered as an IV infusion once every three weeks in patients with solid tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMGN388 | IMGN388 is a human IgG1 anti-integrin antibody conjugated to the maytansinoid, DM4. |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2012-10-01
- Completion
- 2012-12-01
- First posted
- 2008-07-24
- Last updated
- 2013-09-13
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00721669. Inclusion in this directory is not an endorsement.